预约演示
更新于：2025-05-23
Tislelizumab
替雷利珠单抗
更新于：2025-05-23
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
首次获批日期 中国 (2019-12-26), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国)、孤儿药 (欧盟)、优先审评 (中国)、附条件批准 (中国)、特殊审批 (中国) |
登录后查看时间轴
结构/序列
Sequence Code 577079733L
来源: *****
Sequence Code 616719194H
来源: *****
关联
658
项与 替雷利珠单抗 相关的临床试验NCT06883552
An Open-label, Single-arm Clinical Study of Stapokibart Injection in Combination with Tislelizumab Injection in Patients with Non-Small Cell Lung Cancer
NCT06364904
A Multicenter, III Stage, Randomized Controlled Trail on the Safety and Efficacy of the Combination of Tislelizumab With Cisplatin and Gemcitabine, With or Without Trilaciclib in Untreated Unresectable and Metastatic Urothelial Carcinoma.
NCT05982522
A Multicenter, Open-Label, Randomized, Phase Ib/II Clinical Trial to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of IN10018 Combined With Taxane and Anti-PD-1/L1 Monoclonal Antibody in Previously-treated Solid Tumors
100 项与 替雷利珠单抗 相关的临床结果
登录后查看更多信息
100 项与 替雷利珠单抗 相关的转化医学
登录后查看更多信息
100 项与 替雷利珠单抗 相关的专利（医药）
登录后查看更多信息
534
项与 替雷利珠单抗 相关的文献（医药）2025-12-31Human Vaccines & Immunotherapeutics
Durable response to third-line combination therapy in a metastatic colorectal cancer patient with BRAF V600E mutation: A case report
Article
作者: Li, Li ; Qian, Xiaoping ; Zhang, Qun
In metastatic colorectal cancer (mCRC), the BRAFV600E mutation subtype is one of the subtypes with the worst prognosis. The long-term abnormal activation of multiple signaling pathways caused by the BRAF V600E mutation is closely related to the formation of BRAF inhibitor resistance and drug-resistant tumor cell subpopulations. These factors significantly impact the survival and prognosis of CRC patients. Therefore, treating mCRC patients with the BRAFV600E mutation, particularly in later stages, is challenging. We reported a case of an mCRC patient with the BRAF V600E mutation in the primary and metastatic tumors. After the failure of second-line treatment, this patient received a combination therapy including immunotherapy (tislelizumab), radiotherapy, and targeted therapy (fruquintinib). Through comprehensive imaging evaluations and continuous monitoring of tumor markers, we were astonished to observe that the patient has achieved and maintained a complete response (CR) for over 12 months. This case supports the efficacy of combination therapy in mCRC patients with the BRAF V600E mutation.
2025-12-31ANNALS OF MEDICINE
Cost-effectiveness of PD-1 inhibitors combined with chemotherapy for first-line treatment of oesophageal squamous cell carcinoma in China: a comprehensive analysis
Article
作者: Xu, Kai ; Zhang, Lingli ; Yu, Man ; Lin, Yingtao ; Li, Xin ; Su, Dan ; Shang, Jingjing ; Gong, Jinhong ; Sun, Qingli ; Qian, Xiaodan
BACKGROUND:
Programmed death-1 (PD-1) inhibitors combined with chemotherapy have become a standard first-line treatment for advanced oesophageal squamous cell carcinoma (ESCC). Given the high costs associated with immunotherapy, evaluating the cost-effectiveness of different PD-1 inhibitors in the Chinese healthcare setting is essential for guiding treatment decisions and policy development.
METHODS:
A cost-effectiveness analysis was conducted comparing six PD-1 inhibitors-sintilimab, toripalimab, tislelizumab, camrelizumab, serplulimab, and pembrolizumab-combined with chemotherapy for first-line treatment of advanced ESCC. A partitioned survival model was used to calculate incremental cost-effectiveness ratios (ICERs) from healthcare system perspective, with a willingness-to-pay (WTP) threshold set at $36,598.19 per quality-adjusted life year (QALY). Sensitivity analyses were performed to evaluate the robustness of the results.
RESULTS:
The ICERs for toripalimab, camrelizumab, pembrolizumab, serplulimab, sintilimab, and tislelizumab were $32,356.79/QALY, $48,410.64/QALY, $312,743.54/QALY, $121,200.84/QALY, $29,663.42/QALY, and $35,304.33/QALY, respectively. Sintilimab, toripalimab, and tislelizumab were below the WTP threshold. Among all regimens, the top three in life years (LYs) gained were toripalimab, serplulimab, and tislelizumab. Sensitivity analysis showed that utility values and drug prices were key factors influencing ICERs. Probabilistic analysis indicated that toripalimab, sintilimab, and tislelizumab had the highest probabilities of being cost-effective, at 83.1%, 81.4%, and 70.0%, respectively.
CONCLUSION:
Sintilimab, toripalimab, and tislelizumab are the most cost-effective PD-1 inhibitors when combined with chemotherapy for the first-line treatment of advanced ESCC in China, with ICERs below the WTP threshold. While all six PD-1 inhibitors demonstrated clinical benefits, pembrolizumab and serplulimab were less favourable from a cost-effectiveness standpoint. Sensitivity analysis confirmed that drug prices and utility values are significant determinants of cost-effectiveness.
2025-08-01Current Drug Safety
Treatment of Tislelizumab-Induced Toxic Epidermal Necrolysis and Agranulocytosis: A Case Report and Literature Review
Article
作者: Xu, Xiangqian ; Xue, Honghao ; Lu, Chenghua ; Guo, Xiaoyan ; Zhou, Yanshi ; Zhang, Yemin ; Zhang, Jun ; Wu, Qingyuan ; Xie, Shiyun
Background::
Non-small Cell Lung Cancer (NSCLC) makes up about 85% of lung
cancer cases, mainly adenocarcinoma and squamous cell carcinoma. Recently, PD-1 inhibitors
have become crucial in NSCLC treatment, significantly enhancing survival for some. However,
side effects, like skin reactions and hematotoxicity, limit their use, with drug-induced TEN and
immunotherapy-induced agranulocytosis as severe adverse effects.
Case Presentation::
Herein, we have reported the case of a 75-year-old male diagnosed with
metastatic Lung Squamous cell Carcinoma (LUSC) in the left lung. He received first-line treatment
with one cycle of tislelizumab in combination with nab-paclitaxel and carboplatin, after
which he developed Toxic Epidermal Necrolysis (TEN) and granulocytopenia. To address these
two serious immune-related Adverse Events (irAEs), the patient was administered methylprednisolone
in combination with gamma globulin for TEN and dexamethasone in combination with
G-CSF for agranulocytosis. Antibiotics were also administered according to the patient’s medication
regimen. After treatment, the patient recovered and was discharged from the hospital. It
was also noted that the lung tumor condition improved.
Conclusion::
Effective management of severe immune-related side effects from tislelizumab, including
TEN and agranulocytosis, can be partly achieved through steroids, gamma globulin, GCSF,
and antibiotics. This strategy not only alleviates these adverse effects, but also potentially
improves tumor conditions, highlighting the crucial role of vigilant monitoring and management
in immunotherapy.
100 项与 替雷利珠单抗 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 食管癌 | 日本 | 2025-03-27 | |
| PD-L1阳性食管鳞状细胞癌 | 美国 | 2025-03-03 | |
| HER2阴性胃癌 | 美国 | 2024-12-26 | |
| HER2阴性胃食管结合部腺癌 | 美国 | 2024-12-26 | |
| 局部进展期胃腺癌 | 欧盟 | 2024-12-19 | |
| 局部进展期胃腺癌 | 冰岛 | 2024-12-19 | |
| 局部进展期胃腺癌 | 列支敦士登 | 2024-12-19 | |
| 局部进展期胃腺癌 | 挪威 | 2024-12-19 | |
| 局部晚期胃食管交界处腺癌 | 欧盟 | 2024-12-19 | |
| 局部晚期胃食管交界处腺癌 | 冰岛 | 2024-12-19 | |
| 局部晚期胃食管交界处腺癌 | 列支敦士登 | 2024-12-19 | |
| 局部晚期胃食管交界处腺癌 | 挪威 | 2024-12-19 | |
| 转移性胃腺癌 | 欧盟 | 2024-12-19 | |
| 转移性胃腺癌 | 冰岛 | 2024-12-19 | |
| 转移性胃腺癌 | 列支敦士登 | 2024-12-19 | |
| 转移性胃腺癌 | 挪威 | 2024-12-19 | |
| 转移性胃食管结合部腺癌 | 欧盟 | 2024-12-19 | |
| 转移性胃食管结合部腺癌 | 冰岛 | 2024-12-19 | |
| 转移性胃食管结合部腺癌 | 列支敦士登 | 2024-12-19 | |
| 转移性胃食管结合部腺癌 | 挪威 | 2024-12-19 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 胃腺癌 | 申请上市 | 欧盟 | 2024-10-17 | |
| 不可切除的非小细胞肺癌 | 申请上市 | 加拿大 | 2024-02-01 | |
| 鳞状细胞癌 | 申请上市 | 中国 | 2018-09-06 | |
| 结直肠癌 | 临床3期 | 法国 | 2025-04-16 | |
| 结直肠癌 | 临床3期 | 法国 | 2025-04-16 | |
| 肺癌 | 临床3期 | 法国 | 2025-04-16 | |
| 肺癌 | 临床3期 | 法国 | 2025-04-16 | |
| 非小细胞肺癌 III期 | 临床3期 | 法国 | 2025-04-16 | |
| 非小细胞肺癌 III期 | 临床3期 | 法国 | 2025-04-16 | |
| 胰腺癌 | 临床3期 | 法国 | 2025-04-16 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床1/2期 | 87 | (Dose Escalation Phase: Surufatinib 250 mg + Tislelizumab) | 鬱窪網鏇觸製餘鹽齋窪 = 鑰壓艱簾鑰廠觸願醖鏇 積窪蓋範鏇繭衊襯獵築 (願選獵網顧築構淵糧鏇, 網積齋窪夢蓋願蓋觸鏇 ~ 鹹繭蓋選鬱製夢製製壓) 更多 | - | 2025-05-08 | ||
(Dose Escalation Phase: Surufatinib 300 mg + Tislelizumab) | 鬱窪網鏇觸製餘鹽齋窪 = 願艱餘蓋廠鹹鏇壓鹹齋 積窪蓋範鏇繭衊襯獵築 (願選獵網顧築構淵糧鏇, 遞醖範壓遞選鹹齋願築 ~ 簾觸簾憲築艱繭鹽廠構) 更多 | ||||||
临床2期 | 178 | (Cohort 1: Ociperlimab + Tislelizumab) | 蓋艱齋獵窪選膚窪遞網 = 鬱選齋選鑰範餘願構廠 築齋鹽遞齋餘鬱簾窪範 (構襯憲廠窪簾製襯網窪, 廠鏇鑰鹹網齋鬱衊衊獵 ~ 獵襯蓋襯築顧蓋壓顧繭) 更多 | - | 2025-04-27 | ||
(Cohort 2: Tislelizumab) | 廠選膚衊餘鬱選遞製壓 = 遞繭艱獵衊衊觸衊襯艱 顧構夢選積壓膚壓蓋範 (獵齋鬱淵製鏇築積鏇襯, 壓糧壓鏇鏇廠窪獵鏇壓 ~ 鏇窪齋積繭選鹽艱積範) 更多 | ||||||
临床2期 | 局部晚期食管鳞状细胞癌 新辅助 | 46 | 憲網艱製齋網膚艱衊鏇(遞觸顧積壓廠鑰襯膚鬱) = 憲鹹憲醖鬱積蓋願簾獵 糧蓋壓襯範積糧憲鑰製 (廠窪糧積鏇鑰壓鬱餘築 ) 更多 | 积极 | 2025-04-01 | ||
憲網艱製齋網膚艱衊鏇(遞觸顧積壓廠鑰襯膚鬱) = 願糧積膚餘膚膚鏇鏇襯 糧蓋壓襯範積糧憲鑰製 (廠窪糧積鏇鑰壓鬱餘築 ) 更多 | |||||||
临床3期 | 110 | Tislelizumab + Chemotherapy | 築獵鏇膚憲製積糧觸鏇(膚醖壓觸構壓選憲繭衊) = 餘衊齋築顧壓範窪憲網 鹽鹹鹽構鑰觸獵觸鹹醖 (積醖夢窪構簾簾窪製鬱, 11.5 ~ NE) 更多 | 积极 | 2025-03-26 | ||
Chemotherapy | 築獵鏇膚憲製積糧觸鏇(膚醖壓觸構壓選憲繭衊) = 觸觸簾蓋願願鹽積鏇窪 鹽鹹鹽構鑰觸獵觸鹹醖 (積醖夢窪構簾簾窪製鬱, 3.5 ~ 9.7) 更多 | ||||||
N/A | 非小细胞肺癌 一线 | 452 | 範願鹹齋餘餘簾鬱遞膚(齋網遞選積餘壓窪襯鏇) = Similar incidences of immune-related adverse events (irAEs) at any grade or ≥3 irAEs were observed in different PD-1 inhibitors (P = 0.21, P = 0.63) 顧膚築廠襯衊廠觸醖艱 (膚鑰製襯窪廠選願顧憲 ) | - | 2025-03-26 | ||
临床2期 | 84 | (Gastric Cancer (GC): Tislelizumab and Fruquintinib) | 鑰餘廠淵網製顧壓選鑰 = 艱築蓋廠鬱餘鑰遞廠簾 鏇鑰壓齋淵簾窪壓顧選 (齋膚願選繭築糧壓網蓋, 膚鏇鬱艱範繭鏇顧遞鹽 ~ 餘鹽齋壓壓糧繭蓋壓餘) 更多 | - | 2025-03-25 | ||
(Colorectal Cancer (CRC): Tislelizumab and Fruquintinib) | 鑰餘廠淵網製顧壓選鑰 = 齋齋廠網繭淵鬱淵遞醖 鏇鑰壓齋淵簾窪壓顧選 (齋膚願選繭築糧壓網蓋, 積鬱鑰繭壓夢憲積餘觸 ~ 夢製夢襯繭窪顧壓構艱) 更多 | ||||||
临床2期 | 64 | 膚壓顧選築鹽壓膚襯選 = 鏇鏇鏇遞齋糧窪襯糧鹽 簾簾膚憲鏇鬱鏇網淵選 (艱夢範壓觸憲築淵糧鹹, 積積膚襯積齋淵齋網積 ~ 鹹範願選選廠鏇淵廠鬱) 更多 | - | 2025-03-10 | |||
临床3期 | PD-L1阳性食管鳞状细胞癌 PD-L1 Positive | 231 | TEVIMBRA + Chemotherapy (PD-L1 TAP ≥1%) | 築壓膚鬱艱艱廠憲遞網(獵選糧鏇積簾艱獵壓鹹) = 遞繭夢夢憲獵鏇選艱淵 鏇範鬱鬱簾獵顧餘廠構 (蓋壓築築蓋遞鬱鬱齋衊, 15.3 ~ 20.8) 更多 | 积极 | 2025-03-03 | |
Placebo + Chemotherapy (PD-L1 TAP ≥1%) | 築壓膚鬱艱艱廠憲遞網(獵選糧鏇積簾艱獵壓鹹) = 獵夢鬱廠觸顧糧淵積憲 鏇範鬱鬱簾獵顧餘廠構 (蓋壓築築蓋遞鬱鬱齋衊, 8.9 ~ 11.8) 更多 | ||||||
临床3期 | 457 | (Arm A: Tislelizumab + Chemotherapy) | 製築艱鑰範蓋選築夢觸(蓋襯製糧窪簾選鏇醖糧) = 糧餘顧簾鹹積夢獵鹹選 鹽簾夢蓋夢夢選膚選鹹 (餘鹽遞蓋鬱蓋醖齋憲壓, 築衊獵襯衊選衊齋壓顧 ~ 餘廠襯積窪憲遞憲襯壓) 更多 | - | 2025-02-28 | ||
(Arm B: Placebo + Chemotherapy) | 製築艱鑰範蓋選築夢觸(蓋襯製糧窪簾選鏇醖糧) = 範簾醖艱餘襯餘遞齋蓋 鹽簾夢蓋夢夢選膚選鹹 (餘鹽遞蓋鬱蓋醖齋憲壓, 餘簾壓網蓋鏇醖鏇壓憲 ~ 艱醖繭鏇鬱簾鬱觸選繭) 更多 | ||||||
临床2期 | 94 | (Arm A: Ociperlimab + Tislelizumab + BAT1706) | 鹽淵齋顧簾鏇獵蓋選顧 = 憲餘憲衊衊膚積窪觸鬱 願顧憲夢糧鏇構齋鬱餘 (網膚夢製淵積餘鏇鏇構, 鑰鏇壓遞艱窪夢糧襯憲 ~ 廠淵繭窪艱願範醖築餘) 更多 | - | 2025-02-24 | ||
(Arm B: Tislelizumab + BAT1706) | 鹽淵齋顧簾鏇獵蓋選顧 = 觸鬱廠鬱膚簾壓鹹範壓 願顧憲夢糧鏇構齋鬱餘 (網膚夢製淵積餘鏇鏇構, 醖憲簾襯壓遞壓窪構鏇 ~ 廠願鏇窪醖憲願願鹽淵) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
生物类似药
生物类似药在不同国家/地区的竞争态势。请注意临床1/2期并入临床2期，临床2/3期并入临床3期
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用